Gavi works with WHO to identify candidate vaccines to be considered for Gavi support on an ongoing basis. Once preliminary safety and immunogenicity data is available for a candidate vaccine (usually in phase 2a/b), a “living assessment” is developed. This includes preliminary information on disease risk and burden, vaccine impact and feasibility, and determines whether Gavi’s engagement has a comparative advantage.

A full investment case for decision by the Gavi Board is triggered by one of the following: a defined pathway to licensure, an updated WHO recommendation or an urgent public health need (eg disease epidemic). Recommendations on investment could be taken to the Board for decision as part of the VIS or as…